R&D channel feed

On the heels of GW's epilep­sy win, Wall Street dar­ling Zo­genix shares pos­i­tive PhI­II da­ta on ri­val drug

7 years ago

Hop­ing to shake Al­ler­gan/Shire's dry eye dom­i­nance, Oys­ter Point posts pos­i­tive Phase IIb da­ta for ri­val drug

7 years ago

Ra­maswamy’s Der­ma­vant bags GSK’s PhI­II-ready pso­ri­a­sis drug in $330M deal — eye­ing a ma­jor league con­test

7 years ago
Pharma

No­var­tis joins the Big Phar­ma ex­o­dus out of an­tibi­otics, dump­ing re­search, cut­ting 140 and out-li­cens­ing pro­grams

7 years ago

No­var­tis punts a late-stage PI3K drug with a wor­ry­ing safe­ty pro­file to one of Chi­na’s up­start biotechs

7 years ago
Pharma

Genen­tech vet Myr­tle Pot­ter takes a lead­ing role in Vivek Ra­maswamy's fast-mov­ing Vant ops

7 years ago
People

Aquinox dis­cards lead drug, chops half of its staff in wake of PhI­II dis­as­ter

7 years ago

A 7-year-old al­liance be­tween Cel­gene and Ac­celeron is pay­ing off with more promis­ing PhI­II da­ta for lus­pa­ter­cept

7 years ago

Cy­tori shares surge on mixed re­sults for its PhI erec­tile dys­func­tion study

7 years ago

Cash-strapped Reg­u­lus braces for dras­tic down­siz­ing while hit­ting the brakes on lead pro­grams

7 years ago
Pharma

Years in the un­mak­ing, CTI’s Pix­u­vri fails a piv­otal PhI­II com­bo study for lym­phoma — can it re­main on the mar­ket?

7 years ago

Pop­u­lar ke­to di­et set to be test­ed in hu­mans to see if it can amp up ef­fect of weak PI3K drugs

7 years ago

Fo­cused on re­build­ing the pipeline, Ax­o­van­t's new crew as­sem­bles an­oth­er pre­clin­i­cal gene ther­a­py deal

7 years ago
Pharma

Ap­peas­ing ac­tivist in­vestors, Iron­wood cuts 40 staffers at the start of com­pa­ny split

7 years ago
People
Pharma

That Alzheimer's drug that flunked a PhII? On sec­ond look, Bio­gen/Ei­sai say it's a win­ner

7 years ago

THC ther­a­py tanks in PhI, send­ing Zyner­ba's stock tum­bling yet again

7 years ago

No­var­tis dumps world­wide rights to an Aveo drug, and the lit­tle biotech is not hap­py with them

7 years ago

Sanofi gets se­ri­ous in Chi­na with plans to hire 300 for $76M R&D site in Cheng­du

7 years ago
China

Af­ter clos­ing the gap on new hires, FDA could face an ex­o­dus of top reg­u­la­tors

7 years ago
Pharma

Roche vaults in­to lead in front­line triple neg­a­tive breast can­cer as Tecen­triq/Abrax­ane com­bo aces pro­gres­sion-free sur­vival

7 years ago

Bat­tered Gem­phire shares soar on new triglyc­eride da­ta, but there’s a lot left to prove

7 years ago

Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

7 years ago

Ab­b­Vie re­treats as Gala­pa­gos of­fers mixed PhII CF da­ta, leav­ing a ma­jor al­liance in per­il — Ver­tex shares surge

7 years ago

Bio­gen goes deep in­to biosim­i­lars, slap­ping down $700M for a ma­jor stake in Sam­sung Bioepis

7 years ago
Pharma
First page Previous page 267268269270271272273 Next page Last page
A service from the Financial Times